Related Experiment Video

Updated: Jul 16, 2026

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

Application of pharmacogenomic strategies to the study of drug-induced birth defects

J S Leeder1, A A Mitchell

  • 1Department of Pediatrics, Section of Developmental Pharmacology and Experimental Therapeutics, Children's Mercy Hospitals and Clinics, Kansas city, Missouri, USA. sleeder@cmh.edu

Clinical Pharmacology and Therapeutics
|February 23, 2007
PubMed

Insights

Major birth defects affect 3% of US infants annually, causing over 21% of infant deaths. Future research in pharmacogenomics may help understand congenital malformations and individual susceptibility.

Area of Science:

  • Pediatric Medicine
  • Genetics
  • Public Health

Background:

  • Major birth defects impact approximately 3% of infants, leading to over 150,000 affected births yearly in the U.S.
  • Birth defects are the primary cause of infant mortality, accounting for more than 21% of all infant deaths.
  • The causes and factors influencing susceptibility to most congenital malformations remain largely unknown.

Purpose of the Study:

  • To highlight the significant public health burden of major birth defects.
  • To underscore the current limitations in understanding the etiology and determinants of congenital malformations.
  • To introduce pharmacogenomic analyses as a promising future research direction.

Main Methods:

  • This abstract does not detail specific methods but points to the need for future research.
  • It emphasizes the potential of pharmacogenomic analyses.
  • The focus is on the problem statement and future research avenues.

Main Results:

  • The abstract does not present specific results but outlines the scope of the problem.
  • It indicates that over 150,000 infants are affected by major birth defects annually in the U.S.
  • Birth defects represent the leading cause of infant mortality.

Conclusions:

  • Major birth defects pose a substantial threat to infant health and survival.
  • Current understanding of the causes of congenital malformations is limited.
  • Pharmacogenomic analyses hold promise for advancing the understanding and potential prevention of birth defects.

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...